



# Welcome.









# Longevity market inflection: 'if' or 'when'




Mark O'Connell

'Brilliant'  
*Sunday Times*

'Splendid'  
*Guardian*


'Essential'  
*Irish Times*

'Extraordinary'  
*FinancialTimes*



## To Be a Machine

Adventures Among Cyborgs, Utopians, Hackers, and the Futurists Solving the Modest Problem of Death



INTERESTING TO INVESTORS X

NEW?

AKEINER

MODUSUNA


BICA

US DICA



ANESU WBS

UKTI CHANGEMENT!!

CLATS UM



RESEARCH



	Pre-seed Funding	Seed Funding	Early (A,B)	Series A	Average: \$20m	Average: \$7m
Funding level	• \$5k-\$100k	• \$100-\$2m	• 4, 5	• 6, 7	• 8, 9	
TRL level	• 1, 2	• 2, 3, 4	• 4, 5	• 6, 7	• 8, 9	
TRL level	1. Preliminary idea with well characterized theoretical case 2. Principles are demonstrated through experimentation	2. Principles are demonstrated through experimentation 3. Early proof of concept demonstrated in real life conditions 4. Late proof of concept demonstrated in real life conditions	4. Late proof of concept demonstrated in real life conditions 5. Technology refined and ready for initial human trials	6. Technology has completed initial trials and demonstrates preliminary safety data 7. Technology completes secondary trials and demonstrates further evidence for safety and efficiency	8. Technology completes late stage trials and has all evidence required to prove safety and efficiency 9. Regulatory approval in place and ready to go-to-market	
Investor type	• Grant funding	• Angel • Incubator (e.g. Life Bioscience) • High net worth • Crowd funder • Seed funding syndicate	• Healthcare VC leader • Syndicate	• VC (medium) • Corporate VC	• VC (large) • Corporate VC • Sovereign Wealth • Private equity	
Investment decision	• Portfolio manager (1)	• Individual (2) • Fund leader (3)	• Senior partner (4)	• Senior partner (6)	• Senior partner (7)	
Decision support	• Grant fund researcher • Independent academic	• Research reading • Past experience • 3 <sup>rd</sup> party DD	• Junior partner (5) • Staff researcher • 3 <sup>rd</sup> party DD	• Lead analyst • Staff researcher • Independent analyst group	• Lead analyst • Staff researcher • Seasoned analyst group	
CEO profile	• Professor • PhD	• Founder from Academia	• Founder • Investor's CEO	• Founder • Investor's CEO • Seasoned CEO	• Seasoned CEO	



**1. David**

David has been in industry for 15+ years, career hasn't made too many, but likes the concept of how new life span research conditions and can lead to better products.

**2. Michael**

Michael has made his money and wants to stay engaged in business by investing in companies that he either likes the idea of... or are from sectors where he has experience.

**3. Tristan**

Tristan is young, dynamic and empowered to support Longevity through the funds he has at his disposal.

As head of an incubator, he gets Longevity and is interested in technologies that align with his current portfolio.

**4. Andrew**

Andrew has been in VC for over 15 years, he understands technology and healthcare investing and is yet to be convinced that Longevity is a thing.

However, he does need to progress his current investments on to future funding so will be interested in classifying them as Longevity if this will help.

**6. Jan**

Jan has transformed from an investment banking career into a senior role in commercialisation.


She's not emotional about her investment decisions and will have to convince her partners that any investment is on a sound footing.

**7. Tom**


Tom is a seasoned investment pro. He thinks big, invests big and considers himself a visionary. He has track record has had some big exits.

He's looking for the next big technology category and loves Longevity actually prepared to bet big on earlier stage opportunities.

looking to back in his current portfolio.

	B2C				B2B					
Persona	GenZ <24yrs	Millennial <40yrs	Gen X <56yrs	Boomers <75yrs	Professional Investor (Longevity)	Professional Investor	Biotech Entrepreneur	MedTech / Agetech Entrepreneur	Researcher / Academic	New markets executive
										
Character	Olivia	Ashley	Mike	Sally	Sergey	Janet	Aanya	Lucas	Doug	Anne
Persona	Olivia has a mild interest in health and well being, she has heard of biohacking but isn't sure what it's really all about. She's more driven by body image than health but likes to follow the latest trends.	Ashley likes his sport and tries to keep on top of his weight - mixing a busy career with time in the gym and with friends socialising. He's considering ways to age well but it's not his biggest priority right now, anything easy and proven gets his attention.	Mike's knees ache and he's feeling his years; but still a weekend warrior, Mike has a Whoop band and a plan! Still working and always busy, he's starting to think about retirement and the implications of both his health and finances.	Sally has had a few health scares but she's doing well and quite fancies outdoor swimming as yoga's a bit dull. She loves her grandchildren and wants to avoid hip replacements and dementia and has spare income to invest in health products.	Sergey know his way around the big subjects in longevity. He's always looking for a valid breakthrough opportunity to invest into with other like-minded investors; gowing the longevity economy is very important to him.	Janet gets pitched deals all the time but is only really interested in following deals that have have breakthrough status into large market opportunities. She's heard of longevity but can't see the difference to regular healthcare.	Aanya has completed her PhD at Harvard and has funded her new start-up with grant money and an early investment from angels. Her biotech business addresses a major disease of aging and she's not sure if she should pitch it as longevity or biotech.	Lucas has a degree in engineering and has been through an accelerator programme for his startup which has made him a bit over-confident. The company has angel funding and is looking for the next funding round to finish trials ahead of launch.	Douglas is a professor at a midwest university and specialises in small molecule biology. He's an avid reader of the major journals but is also interested in learning more about longevity and how his work dovetails into the new longevity field.	Anne has worked her way up the ladder with various large enterprises. Having worked both in big pharma and food conglomerates she's now in charge of new product development for future revenue pipelines.
Knowledge about longevity?	Low	Medium	Medium	High	High	Medium	Medium	Medium	High	Low





Page 9 Figure: Longevity companies investment activity analysis by Longevity.Technology, based on Pitchbook data funding data as of 16/09/2022.

# Longevity market inflection: 'now' not 'if' or 'when'


Nobody talks about 'snake oil' anymore; now the questions simply distil down to:

- How quickly will the science be validated?
- How soon will therapies go mainstream?
- How will therapies go mainstream?

**T** The Times

**Holy grail of anti-ageing comes step closer**

Jeff Bezos is among the tech billionaires backing Altos Labs, a new \$3 billion project that has poached leading scientists and Nobel laureates...



**The Guardian**

**Morgan Levine: 'Only 10-30% of our lifespan is estimated to be due to genetics'**


This June she will join Altos Labs, a new \$3bn (£2.2bn) anti-ageing biotech startup whose funders are said to include Jeff Bezos.



**F** Futurism

**Billionaire Launches Startup to Reprogram Human Gene Expression**


Billionaire Coinbase founder Brian Armstrong has launched a new "epigenetic ... called NewLimit, with the goal of greatly extending the human lifespan.



**B** Bloomberg.com

**Watch The \$7.6 Trillion Quest for Longer Life**

The new field of longevity science aims to slow aging and make late-life more livable. But will the science ever work?





# Aging diseases cost a lot!

At some point, internal programming and wear and tear may result in a disease of aging.


Total of annual US-expenditure >>

**USA =  
\$3073bn  
annually**




- Skin
- Digestive system
- Endocrine and metabolic diseases and immunity disorders
- Nervous system
- Musculoskeletal system
- Respiratory system
- Circulatory system


# Aging diseases cost a lot!



# Defining longevity: 3 Targets



# Defining longevity: 3 Targets



Aging pathways, mechanisms and hallmarks					
Epigenetics	Mitochondrial dysfunction	Immuno-modulation	IGF-1	Nf-Kb	Nrf3
DNA repair	Progeronic chronokines	Reproduction	Insulin	IL-1B	PAI
Telomere regulation	Oxidative stress	Glycation	mTOR	P53	Wnt
Proteostasis	Stem cell exhaustion	Defective autophagy	FOXO	Ang-II	SIRT6
Nutrient sensing	Cellular senescence	Androgenic signalling	AMPK	AKT	NAD
Macromolecular damage	Dysregulated microbiome				

# Defining longevity: aging drivers



# Defining longevity: aging drivers

Aging drivers

Longevity thinking:

Target aging drivers to mitigate multiple diseases at same time.



Current thinking:

Treat one disease target at a time.

Aging disease





# Defining longevity: aging drivers

Aging drivers

Longevity thinking:

Target aging drivers to mitigate multiple diseases at same time.

Many of the aging drivers that are implicated as “aging pathways” in preclinical studies are also implicated in the age-related diseases.

Aging is the common and the major risk factor for these chronic diseases

By targeting aging drivers to slow the progression of aging, we will delay the onset of multiple age-related diseases (and early death) collectively, rather than one at a time.

Current thinking:


Treat one disease target at a time.

Aging disease



# Defining longevity: 4 pillars

Every company in the longevity industry is based around these three targets and aim to modulate the trajectory by prevention, diagnostic, renewal, or treatment.



# Example applied to CVD

	Prevention	Diagnostics	Renewal	Treatment
	Prevent damage that accelerates aging and modify longevity determinants and aging drivers.	Early identification of health status and accumulation of aging damage. Diagnostics span across longevity determinants, aging drivers and at the point of aging disease.	Treatment of damage that has occurred. This means direct treatment of an aging disease.	Reversal of damage that has occurred. This includes either accumulated damage before disease has arisen, damage arising from aging drivers, or that which occurs at the point of disease.
<b>Current approach</b>	Prescription medications	ECG, EGG	Pacemaker, lipid-lowering agents	Angioplasty/stents, bypass surgery
<b>Longevity approach</b>	Exercise, Mediterranean diet, longevity supplements	Epigenetic clock to predict CVH (BASE-II)	Treatment of atherosclerosis-related risk (by removal of arterial plaque)	Heart repair by cardiac reprogramming

# Defining longevity: Domains


These are popular market clusters that are frequently used to view the different segments of the longevity industry.

**Biological Age Diagnostics**  
A new era of medicine and longevity.



LongevityTechnology®

**Longevity Neurotech**  
Unlocking the brain's longevity potential.



LongevityTechnology®

**Longevity Supplements**  
A new era of medicine and longevity.



LongevityTechnology®

https://longevity.technology/investment/alerts/

LongevityTechnology®

News Investment Research Lifestyle Videos

Investment portal Raise finance

Dashboard

Investment deals

Investor briefings

**Company alerts**

Investment news

Investment videos

Stock tracker

time and talents may be better applied in other opportunities and endeavours.

<https://www.ldmicro.com/profile/pte/news/6883228102751274>

September 9, 2022

## InsideTracker raises \$15 mn in Series B.

**Inside Tracker**

Also known as: #N/A

LT 2220

220 of 560

InsideTracker, "the ultra-personalized nutrition system," compiles data from DNA tests, blood samples, and reported lifestyle and nutrition habits, and from that creates custom science-backed action plans. The goal is to optimize your body so you can live longer, feel better, and perform to your potential.

Longevity pillar

Prevention  Diagnostic

Longevity domain:

Longevity diagnostics

Location: United States

Year founded: 01-Jan-09

Longevity target: Longevity determinant, Aging Driver

Proprietary analysis by LongevityTechnology, according to Pitchbook Data data as of September 12, 2022

September 8, 2022

## Synthetic Biologics files to sell 2.46M shares of common stock for holders.

Synthetic Biologics files to sell 2.46M shares of common stock for holders.

<https://thefly.com/n.php?id=3577001NaNotics%2008/09/2022%20-%202303>

## Mass General Cancer Center (MGCC) to develop no

MGCC, a program of Massachusetts General Hospital (MGH) in Boston, is developing a new technology to target Tumor Necrosis Factor Receptors, which are tumour-generated immune inhibitors. The technology aims to reduce cancer disease by capturing and clearing pathogenic molecules from blood.

<https://www.massgeneral.org/news/2022/09/08/05083/en/NaNotics-to-Collaborate-with-Mass-General-Cancer-Cent>

# Defining longevity: Domains



Seno-therapeutics



Longevity supplements




Young blood




Longevity diagnostics



Aging in place




Neurotech



Longevity immunity



Discovery platforms




Rejuvenation



Regeneration



Re-programming



Metabolic rejuvenation




Companion longevity



Advanced aesthetics



Repurposed drugs



Microbiome




Longevity genetics



Longevity platforms




Longevity lifestyle



Longevity clinics



Longevity drugs



Functional food



Education




Neuropharma




Reproductive longevity

# Defining longevity

# ... comprehensively




# Longevity investment by domain: the last 5 years









# Longevity investment by domain: the last 5 years



# Domains by investment








# #1 Reprogramming




- Complete cellular reprogramming: iPSCs can differentiate into many different cell types and being derived from the patient's cells reduces any risk of rejection
- Efficiency needs to be increased dramatically whilst avoiding the induction of cancer
- Partial reprogramming: companies are looking to reverse the age of a cell from old to young without losing the cells identity.
- This would have the potential to target many age-related diseases.

# #1 Reprogramming: \$4.41bn invested last 5 years



			 MOGRIFY Transforming Cell Therapy		
Raised to date	\$3.27bn	\$250mn	\$39.72mn	\$34.70mn	\$180mn
Most recent raise	£3bn	\$187.5mn	\$20mn	\$32mn	\$180mn
HQ	California	California	Cambridge	Cambridge	Maryland
Note	A biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease.	Developing cellular drivers of aging therapies to increase healthy human lifespan by 10 years, focusing on cellular reprogramming, autophagy and plasma-inspired therapeutics.	Developer of a cell coding technology designed for a new generation of cell therapies by democratizing access to consistent and functional human cells.	Transforming the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.	A cell engineering company harnessing the power of genetics to replace defective cells.
TRL /clinical stage	3: Pre-clinical in-vitro	3: Pre-clinical in-vitro	4: Pre-clinical in-vivo	4: Pre-clinical in-vivo	4: Pre-clinical in-vivo

## #2 Regeneration








- Over time, our organs, tissues and cells degenerate and are destroyed
- Regenerative medicine could completely revolutionise the medical industry and how we treat disease
- Having the ability to regenerate opens the door to increased longevity
- Replacing older organs, tissues and cells with new optimally functioning ones.






# #2 Regeneration: \$3.66bn invested last 5 years

					
Raised to date	\$883.10mn	\$615mn	\$537.70mn	\$424.46mn	\$273.3mn
Most recent raise	\$44.76mn	\$175mn	\$30mn	\$65.6mn	\$42.30mn
HQ	Melbourne	North Carolina	New Jersey	France	Massachusetts
Note	Mesoblast's novel allogeneic product candidates are mediators that promote tissue repair and modulate immune responses.	Manufacturing off-the-shelf, universally implantable bioengineered human tissues.	Creating cell therapies from placenta. Material arrest or reverse degenerative process by supporting healthy repair of regeneration of organs/tissues.	The CARMAT total artificial heart could, assuming a successful clinical development, potentially save the lives of thousands of patients each year with no risk of rejection and with an enhanced quality of life.	Developer of regenerative therapeutics intended to repair or reverse damage caused by a broad range of degenerative diseases.
TRL /clinical stage	7: Phase 2	7: Phase 2	4: Pre-clinical in-vivo	6: Phase 1	7: Phase 2






# #3 Longevity genetics



- Gene therapy could be a radical solution to treat age-related pathologies (as well as many other diseases)
- A human being who lives in a perfect environment with adequate health care and an exemplary lifestyle would never live past the age of 122
- We are programmed to die and the answer might be in our genetics
- This is one of the reasons why gene therapies are among the most promising therapies for longevity
- Gene-based therapies could target any aging phenotypes and diseases and have been successful in preclinical studies.



# #3 Longevity genetics: \$3.66bn invested last 5 years

					
Raised to date	\$428mn	\$284.60mn	\$225mn	\$221.40mn	\$140mn
Most recent raise	\$180mn	\$1,500bn (acquired)	\$581.60mn (M&A)	\$35.88mn	\$50mn
HQ	San Francisco	London	Cambridge	Paris	California
Note	Restore heart cell function by using viral vectors to deliver healthy copies of genes or other therapeutic payloads	Developer of genetically-defined therapies intended to fight the devastating impact of age-related macular degeneration (AMD).  Was acquired in 2022 by Novartis with upfront cash payment of \$800mn.	Enhanced iPSCs with genetic engineering to enhance authentic cells with specific functions to improve therapeutic effect.  Following a 2016 joint venture with Versant Ventures Bayer acquired its remaining stake in 2019.	Combining a gene therapy-based approach with proprietary technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.	Capsida's initial internal preclinical programmes centre on neurodevelopmental and neurodegenerative disorders, areas in which gene therapies have yet to gain significant traction due to the difficulties of targeting the brain.
TRL /clinical stage	6: Phase 1	6: Phase 1	6: Phase 1	3: Pre-clinical in-vitro	3: Pre-clinical in-vitro





# #20 Pet longevity: \$90mn invested last 5 years




- Dogs are an interesting model for human aging – they have co-evolved with us, and share similar environments to us
- Owners would be happy paying \$10,725 per year to keep save their dog from a life-threatening disease
- Dogs develop age-related diseases just like humans do - laboratory mice often must be bred or altered to have an age-related illness
- As dogs age faster than humans, clinical trials could be conducted in only 3-5 years.
- Creating a drug to extend dog lifespan would provide a platform for similar interventions in humans.

# #20 Pet longevity: \$90mn invested last 5 years







	<b>loyal</b>	 REJUVENATE BIO	 genflow biosciences longer better life	<b>WILD</b>	<b>animal</b> BIOSCIENCE
Raised to date	\$57.3mn	\$19.77mn	\$6.71mn	\$6.55mn	\$1.7mn
Most recent raise	\$20mn	\$3mn	\$4.27mn	\$2mn	\$1.27mn
HQ	California	California	London	Rehovot	Massachusetts
Note	The company's target drugs delay the onset of age-related diseases like cancer, heart diseases, and metabolic diseases.	Developer of a cardio-protective gene therapy designed to increase the health and lifespan of domesticated animals.	Lead compound is an AAV containing transgene encoding cDNA portion of human SIRT6 gene.  Currently in a pivotal anti-aging trial in dogs.  Disclosure: First Longevity Ltd has a commercial interest in Genflow Biosciences Ltd.	Wild animals' evolution results in remarkable resilience to many diseases via potent and balanced microbiome. Wild Biotech translates into novel therapeutics for humans.	Developer of Leap Years™, a chewable supplement for pets that has been scientifically proven to prevent aging at the cellular level to extend the health and vitality to pet's life.
TRL /clinical stage	7: Phase 2	7: Phase 2	4: Pre-clinical in-vivo	6: Phase 1	7: Phase 2

# #15 Longevity supplements: people's aging concerns




# #15 Longevity supplements: \$290mn / last 5 years



	 Amazentis	<b>ELYSIUM</b>	 ChromaDex	 PDL PONCE DE LEON HEALTH	 Seraphina Therapeutics
Raised to date	\$51.9mn	\$66.49mn	\$44mn	\$11.4mn	\$11.70mn
Most recent raise	\$43mn	\$40mn	\$25mn	\$6mn	\$5.50mn
HQ	Lausanne	New York	California	Ireland	California
Note	Mimics the effect of certain foods such as pomegranates to clean up damage in cellular powerhouses called mitochondria optimizing the muscle functions.	Develop NAD+ boosting supplements for cellular metabolism and at-home tests to discover biological age.	The NIAGEN® ingredient is ChromaDex's patent-protected form of nicotinamide riboside (NR). NR is an NAD+ booster.	Specifically focused on creating supplements based on AKG that reverse epigenetic aging to increase health and lifespan in humans, pets and livestock.  Disclosure: First Longevity Ltd is working with PDL to raise equity finance.	Fatty acid supplements, food fortifiers and nutritional interventions to strengthen cells, keep mitochondria working and advance cellular homeostasis to counter age-related breakdown.
TRL /clinical stage	10	10	10	10	10

# #9 Longevity diagnostics








■ Biological age test ■ Health assessment ■ Digital health assessment

- We need an objective, quantifiable biomarker for the aging process that can be tracked in clinical trials.
- If we can resolve a validated aging biomarker, prevention drug design may be even more lucrative than the disease treatment design we have now
- A good longevity diagnostic should:
  1. Be relevant to aging
  2. Should robustly and consistently predict trial endpoints, such as functional ability, disease, or death
  3. Measure reliably overseen by peer-review
  4. React to interventions targeting aging biology.

# #9 Longevity diagnostics: \$1.97bn / last 5 years



					
Raised to date	\$1.17bn	\$335.46mn	\$182.5mn	\$100mn	\$52.18
Most recent raise	\$375mn	\$132.17mn	\$20mn	\$99.64mn	\$8.67
HQ	Colorado	Helsinki	Washington	London	California
Note	By examining proteins at the cellular level, proteomics allows providers to measure and track patient health risks holistically and in real-time and prevent the escalation of disease.	Health data platform that detects disease risks. The Health Data Platform empowers individuals to take better actions to prevent diseases by allowing them access to disease risk information	Decodes precise health insights and biomarkers of various chronic diseases using artificial intelligence and systems biology expertise, enabling healthcare providers to give personalized nutrition precision supplements.	Klotho-based tests and therapies, enabling people to reduce the risk of many aging-related diseases including cancer, chronic inflammation, diabetes, calcification of arteries, vision and memory loss.	Whole-body scans to generate a digital twin of the patient's physical body to quantify, digitize, the data and utilize simulated human physiology and machine learning to predict potential health risks.
TRL /clinical stage	10	10	10	10	10

# Longevity: it's possible for everyone to grow younger



Example of what's possible:


- Chronological age: 55 ... Metabolic age: 47
- Exercise-centered lifestyle
- Curious about health and improvement
- Disposable income
- A long-way from retirement
- Physician-prescribed longevity regime:

- |                              |                                 |
|------------------------------|---------------------------------|
| NMN Booster (NAD+ precursor) | NAC Glutathione Boost           |
| NR Booster (NAD+ precursor)  | Acetyl L-carnitine              |
| Omega 3 High EPA             | MitoPQQ Energy Boost            |
| Co Q10 High Strength         | Promultima (gut bacteria)       |
| Alpha Lipoic Acid            | Vitamin D3 + K2 (high strength) |
| Regular exercise             | Reduced alcohol                 |
| Reduced animal protein       | Intermittent fasting            |

Stage	Birth age	Chronological age	Metabolic age	Chronic diseases	Age-deceleration	Projected death age
No-test	0	54	55	Unknown	100%	85
Epigenetically tested	0	54	47	None	115%	98




# 2022 is a big year despite the challenges







# 2022 is a big year despite the challenges



# 2021 analysis: total raised / deal count / funding type




# 2022 analysis: total raised / deal count / funding type




# Categories of investors: 5 years


- Venture Capital
- Private Equity
- Private Debt
- Co-investment
- Real Assets
- Funds of Funds
- Secondaries
- Other



# Investor activity key growth markets



# Investor activity other markets vs longevity




# Revenue-generating: £1mn seed round currently open



Our advertising-supported media platform enables us to launch and promote our investment deals;

Our unique data sets and extensive network allow us to identify and curate high caliber investment opportunities;

Our data-driven intelligence enables us to identify growth markets and longevity market gaps to exploit.



# Our role: media





# Our role: brokerage

Longevity domain companies: 560


Investor connections (profiled): 1098

① **Prevention**  
Prevent damage that causes aging;

② **Renewal**  
Reversal of damage that has occurred;

③ **Treatment**  
Treatment of damage that has occurred;

④ **Diagnostic**  
Early identification of aging damage.



Pre-seed longevity investors

Longevity biotech platforms

Biotech funds

AgeTech and tech funds

Larger mainstream funds

Family office and HNW capital

Strategic investors (pharma)

# Longevity: it's possible for everyone to grow younger



Example of what's possible:

- Chronological age: 55 ... Metabolic age: 47
- Exercise-centered lifestyle
- Curious about health and improvement
- Disposable income
- A long-way from retirement
- Physician-prescribed longevity regime:

- NMN Booster (NAD+ precursor)
- NR Booster (NAD+ precursor)
- Omega 3 High EPA
- Co Q10 High Strength
- Alpha Lipoic Acid
- Regular exercise
- Reduced animal protein
- NAC Glutathione Boost
- Acetyl L-carnitine
- MitoPQQ Energy Boost
- Promultima (gut bacteria)
- Vitamin D3 + K2 (high strength)
- Reduced alcohol
- Intermittent fasting


Stage	Birth age	Chronological age	Metabolic age	Chronic diseases	Age-deceleration	Projected death age
No-test	0	54	55	Unknown	100%	85
Epigenetically tested	0	54	47	None	115%	98








# Aging is plastic



# Aging is plastic



Aging, as a process, is not fixed to the pace of chronological time; it can speed up or slow down.

We are already:

1. Building exciting new technologies and companies;
2. Establishing a hugely successful industry;
3. Forming amazing investor-returns;
4. Giving everyone multiple more years of health;
5. Eradicating the trauma of disease and death.



# Let's get started!

